• Chimerix Announces Topline Results from Randomized COVID-19 Clinical Trial americanpharmaceuticalreview
    March 05, 2021
    Cantex Pharmaceuticals announced Chimerix, worldwide licensee of Cantex's DSTAT investigational product, has reported promising results of the first cohort of patients hospitalized with COVID-19-associated Acute Lung Injury (ALI), suggesting that ...
PharmaSources Customer Service